Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Sal Milani who wrote (9028)	6/3/1998 3:51:00 PM
From: Sal Milani	Respond to of 23519

To All: From Briefings: Vivus Inc. (VVUS) 7 1/32 -1 23/32: --UPDATE-- Genesis Merchant Group Securities downgrades male impotence product concern from long-term "buy" to "hold" following the release of several studies on its MUSE impotence product; there does not appear to be overwhelming support among urologists for using MUSE as the preferred form of treatment as efficacy rates range from 10% to 58%.....

To: Sal Milani who wrote (9028)	6/3/1998 3:58:00 PM
From: Colby	Read Replies (1) \| Respond to of 23519

What is Briefings? When the author says, "We would expect this latest data to only increase the number of shareholders who join one of the more than half-dozen class-action suits that have been filed against the company. Maybe Cruttenden Roth should add its name to that list." who is "we" referring to. Enough is enough. VVUS has been selling product for 18 months. How is it that now, it doesn't work, the lawsuits are being promoted, and analysts have missed the boat. This is quite a campaign, intentional or not, against VVUS. One or two articles, I think maybe there is something about the company I need to investigate, 5+ articles and I think maybe there is something about the source(s) that requires a little investigation. Next headline please, Colby